The Medicines Patent Pool (MPP) is pleased to present its annual report for the year 2022. Through strategic partnerships and dedicated efforts, MPP expanded its reach, fostered innovation, and further strengthened its position as a leading force in ensuring access to essential medicines and health technologies in low- and middle-income countries.

Click Here to Access the 2022 Annual Report

Access Digital Version of MPP’s 2022 Annual Report


In summary we have:

  • Expanded our portfolio of signed licences, with four singed in 2022 reaching a total of 36 licenses with originator companies since our inception in 2010;
  • We have established 58 partnerships with manufacturing partners across 16 countries;
  • 25 products have been developed or supplied by MPP licensees;
  • 34.69 billion doses of treatment have been supplied by MPP licensees;
  • USD 1.5 billion of actual financial savings have been made by the international community by accessing MPP-licensed products;

The growth in 2022 was driven by breakthrough licence agreements in long-acting formulations, including cabotegravir with ViiV Healthcare and Medincell technology for malaria. Additionally, we achieved a significant milestone in the fight against COVID-19 by signing a licence for ensitrelvir fumaric acid with Japanese company Shionogi. MPP also demonstrated remarkable progress signing its first ever licence in addressing non-communicable diseases (NCDs) through a license agreement with Novartis for the cancer treatment nilotinib.

Furthermore, MPP fostered growth by engaging with a higher number of generic manufacturers. The number of generic manufacturers who had signed a licence agreement with MPP peaked in 2022, and we are delighted to see so many applications from different countries.

Moreover, MPP experienced an expansion in the number of partners and collaborators, that allowed us to leverage expertise, resources, and support for our mission. The mRNA Technology Transfer Programme also witnessed notable growth in funding, enabling the progamme to grow to enhance its capabilities in this crucial area of vaccine security in low- and middle-income countries.